Xigduo XR, a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adults with type-2 diabetes (T2D) as an adjunct to diet and exercise to improve glycaemic control.
“People living with type-2 diabetes often have comorbidities such as heart failure and chronic kidney disease, leading to cardiorenal events which are the primary causes of death and hospitalisation in this patient population. There is a need for effective and innovative therapies that can both lower the occurrence of these events and also help improve treatment adherence, which often undermines glycaemic control. Today’s welcome approval reinforces SGLT2 inhibitors and metformin as foundational treatments for type-2 diabetes patients in China and represents an important step forward in better management of this condition,” says Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZeneca.
Xigduo XR combines two anti-hyperglycaemic agents with complementary mechanisms of action: dapagliflozin (trade name, Forxiga), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which has been approved in China for the treatment of adults with T2D, heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD), and metformin hydrochloride (HCl) extended release, a biguanide, in a once-daily oral tablet. It is the only fixed-dose combination of this kind to be approved in China and provides a first-line treatment option that can improve glycaemic control in T2D patients.
The approval by China’s NMPA was based on a local bioequivalence study and supported by the global diabetes program for Xigduo XR, which provided clinical evidence for the efficacy and safety profile of dapagliflozin and metformin immediate-release (IR) or XR tablets in patients inadequately controlled on metformin.
Xigduo XR is approved in the US, Australia and other regions.
Photo of Ruud Dobber: AstraZeneca